![Hans Joachim Bochtler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hans Joachim Bochtler
Directeur Technique/Scientifique/R&D chez Neovii Biotech GmbH
Provenance du réseau au premier degré de Hans Joachim Bochtler
Entité | Type d'entité | Industrie | |
---|---|---|---|
Neovii Biotech GmbH
![]() Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany.
4
| Subsidiary | Biotechnology | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hans Joachim Bochtler via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Coley Pharmaceutical Group, Inc.
![]() Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Corporate Officer/Principal | |
ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Affimed GmbH
![]() Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member | |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
ADMA BIOLOGICS, INC. | Biotechnology | Director/Board Member | |
AFFIMED N.V. | Biotechnology | Director/Board Member | |
BIOTEST AG | Pharmaceuticals: Other | Chairman | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree | |
Coley Pharmaceutical GmbH
![]() Coley Pharmaceutical GmbH Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
ATON | Pharmaceuticals: Major | Director/Board Member | |
Twelve Bio
![]() Twelve Bio Miscellaneous Commercial ServicesCommercial Services Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023. | Miscellaneous Commercial Services | Chairman | |
PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
ARIX BIOSCIENCE PLC | Investment Managers | Corporate Officer/Principal | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Chairman | |
OMEICOS Therapeutics GmbH
![]() OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
BIO Deutschland
![]() BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Rigontec GmbH
![]() Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Universität zu Köln | College/University | Doctorate Degree | |
Lindis Blood Care GmbH
![]() Lindis Blood Care GmbH Medical SpecialtiesHealth Technology Lindis Blood Care GmbH engages in the development and manufacture of autologous blood transfusion devices. It specializes in blood transfusion and intraoperative blood salvage. The company was founded by Horst Lindhofer and Franzpeter Bracht in January 2018 and is headquartered in Hennigsdorf, Germany. | Medical Specialties | Founder |
Statistiques
Internationale
Allemagne | 16 |
Etats-Unis | 7 |
Danemark | 4 |
Royaume-Uni | 3 |
France | 2 |
Sectorielle
Health Technology | 18 |
Commercial Services | 6 |
Consumer Services | 4 |
Finance | 2 |
Opérationnelle
Director/Board Member | 10 |
Corporate Officer/Principal | 7 |
Chief Executive Officer | 5 |
President | 5 |
Chairman | 4 |
Relations les plus connectées
Insiders | |
---|---|
Bernhard R. M. Ehmer | 16 |
Christian Schetter | 12 |
Horst Lindhofer | 2 |
Thomas Gottwald | 1 |
- Bourse
- Insiders
- Hans Joachim Bochtler
- Connexions Sociétés